Perrigo (PRGO) Declares $0.145 Quarterly Dividend; 0.6% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Guggenheim Cuts PT On Perrigo (PRGO) By 30%
April 27, 2016 6:37 AM EDTGuggenheim analyst, Louise Chen, thinks Perrigo Co. (NYSE: PRGO) stock could experience downward pressure ahead of 1Q16 earnings but that earnings visibility going forward is likely to improve. Due to the executive departure, she cut her PT from $185 to $125 but maintained a Buy... More
S&P Downgrades Perrigo (PRGO) to 'BBB-'; Sees Weakness in High-Margin Business
April 26, 2016 12:14 PM EDTStandard & Poor's Ratings Services lowered all of its ratings on Perrigo Co. plc (NYSE: PRGO), including the corporate credit rating to 'BBB-' from 'BBB'. The outlook is stable. Reported debt outstanding as of Dec. 31, 2015 was about $6 billion.
"The downgrade reflects our expectation for weakness in Perrigo's high-margin generic pharmaceutical business, largely resulting from intensifying competition and lower pricing, and a further expected decline in the recently acquired European branded consumer business," said Standard & Poor's credit analyst Gerald Phelan. "As a result, we now forecast adjusted debt-to-EBITDA in the mid-3x area over... More
